Omni Ab Status
The company was acquired by Ligand Pharmaceuticals (NAS:LGND) for $178 million on December 29, 2015. The deal included $92.6 million in cash and $85.4 million in Ligand common stock.
Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
Year Founded
2007
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly VC-backed
Omni Ab News and Updates
Flight Inspection Market A Latest Research Report to Share Market Insights and Dynamics to 2028 – The Bisouv Network
The Bisouv Network | February 27, 2021
Latest Privacy Glass Market Report – Global Industry Analysis, Development, Scope, Share, Trends, Forecast to 2026 – Express Keeper
Express Keeper | February 26, 2021
Flight Inspection Market Size, Share, Growth Survey 2021 to 2028 and Industry Analysis Report – Express Keeper
Express Keeper | February 26, 2021
RFID Tags Market Study Based on Shares, Current Opportunities with Future Growth Scenario by 2026 – The Courier
The Courier | February 25, 2021
Omni Ab Primary Industry Sector / Group / Code
Omni Ab's Trends
Headquarters
-
HQ Address Line 12747 Ross Road
-
HQ Address Line 2Suite A
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94303
-
HQ CountryUnited States
Omni Ab's Keywords
mood_badFeed is empty.
Add a review